Evidence map›Paper›PMID 41683581›Full record

ReviewInternational journal of molecular sciences2026

Bridging Osteoimmunology and Regenerative Therapy: The Role of MSCs and Extracellular Vesicles.

Itziar Álvarez-Iglesias, Alice Colombo, Luis Gil-de-Gómez, Daniel García-Sánchez, Alberto González-González, Flor M Pérez-Campo

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Itziar Álvarez-IglesiasDepartamento de Biología Molecular, Universidad de Cantabria-IDIVAL, 39011 Cantabria, Spain.ORCID 0009-0002-6830-2286
Alice ColomboDepartamento de Biología Molecular, Universidad de Cantabria-IDIVAL, 39011 Cantabria, Spain.ORCID 0009-0009-8431-670X
Luis Gil-de-GómezDepartamento de Biología Molecular, Universidad de Cantabria-IDIVAL, 39011 Cantabria, Spain.ORCID 0000-0002-7864-3976
Daniel García-SánchezDepartamento de Biología Molecular, Universidad de Cantabria-IDIVAL, 39011 Cantabria, Spain.ORCID 0000-0002-1754-9185
Alberto González-GonzálezDepartamento de Biología Molecular, Universidad de Cantabria-IDIVAL, 39011 Cantabria, Spain.ORCID 0000-0002-2336-8284
Flor M Pérez-CampoDepartamento de Biología Molecular, Universidad de Cantabria-IDIVAL, 39011 Cantabria, Spain.ORCID 0000-0002-9872-7990

Funding

Instituto de Salud Carlos III PI25/01177
6 · The paper itself

Abstract

Bone homeostasis and regeneration depend on tightly regulated interactions between skeletal cells and the immune system within the bone microenvironment. Disruption of this crosstalk by ageing, chronic inflammation, or systemic disease contributes to osteoporosis, inflammatory bone loss, and impaired fracture healing. Osteoimmunology has reframed bone biology as an immune-regulated process, highlighting mesenchymal stem cells (MSCs) as central coordinators of bone-immune communication. Beyond their differentiation capacity, MSCs act primarily through paracrine mechanisms, releasing a secretome composed of soluble factors and extracellular vesicles (EVs) that modulate immune responses, regulate osteoblast and osteoclast activity, promote angiogenesis, and support extracellular matrix remodelling. MSC-derived EVs have emerged as key nanoscale mediators that transfer bioactive cargo to target cells in a context-dependent manner, enabling precise regulation of osteoimmune processes. This review summarises current knowledge on the role of MSCs in osteoimmunology, with a focus on how their secretome and EVs integrate immune modulation with bone regeneration. We discuss the mechanisms underlying MSC-mediated regulation of innate and adaptive immune cells, examine emerging cell-free therapeutic strategies based on secretome and EV delivery, and outline the main challenges that must be addressed to advance these approaches towards clinical application.

Indexed as

Bone RegenerationExtracellular VesiclesMesenchymal Stem CellsRegenerative MedicineAnimalsBone and BonesHumansImmunomodulationOsteoclastsbone regenerationcell-free therapyextracellular vesiclesimmunomodulationmesenchymal stem cellsosteoimmunology

Identifiers

PMID41683581
PMCPMC12898135

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.